Telomere Trial
- Lauren Donahoo
- Sep 17, 2025
- 1 min read
Updated: Sep 19, 2025
Telomere shortening has been linked to a worse prognosis for patients with PF. Additional of thymidine to cell lines or to stem cells from patients with dyskeratosis congenita (a disease caused by mutations in genes that maintain telomeres) was shown to lengthen telomeres dramatically. “Thymidine nucleotide metabolism controls human telomere length”, published in Nat. Genet.
Funding by Three Lakes 12-20 founders is supporting a phase I clinical trial to assess the safety and biological effects of deoxycytidine plus thymidine.
The principal investigator for these studies is Suneet Agarwal, MD., PhD., Co-Program Leader for the Stem Cell Transplant Center, Dana Farber/Boston Children’s Cancer and Blood Disorders Center and Associate Professor of Pediatrics, Harvard Medical School.